| (Values in U.S. Thousands) | Sep, 2019 | Jun, 2019 | Mar, 2019 | Dec, 2018 | Sep, 2018 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -4,040 | -3,650 | -4,840 | -6,630 | -7,250 |
| Net Income Growth | -10.68% | +24.59% | +27.00% | +8.55% | +11.48% |
Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aevi Genomic Medicine Inc. is focused on genomic medicine. The Company focuses on translating genetic discoveries into novel therapies. Its product candidates include AEVI-001 and AEVI-002 which are in clinical trial stage. Aevi Genomic Medicine Inc., formerly known as Medgenics Inc., is based in WAYNE, United States.
Fiscal Year End Date: 12/31